Rani Therapeutics Reports Third Quarter 2026 Financial Results; Provides Corporate Update

~ Accepted into the U.S. FDA’s Emerging Technology Program (ETP), enabling early FDA engagement to support development of the RaniPill® platform technology ~ ~ Enrollment continues in RT-114 Phase 1a expansion cohort;